J.C. Penney Offers A ‘Poison Pill’ Rights Agreement, Citi Says Sell

HFA Padded
HFA Staff
Published on
Updated on

J.C. Penney Company, Inc. (NYSE:JCP) announced a shareholder rights program yesterday that seeks to protect the company from a takeover attempt. A new report on the company, out of Citigroup Inc (NYSE:C), takes a look at the likely effect of the new scheme. Unfortunately for shareholders, the analyses don’t see many positives in the poison pill. The analyst, Deborah L. Weinswig, maintained her price target of $11 on the company and rated it a Sell. On today’s market, shares in the company were flat, trading at $13.20 per share at time of writing. Shares in the struggling retailer have been dropping…

This content is exclusively for paying members of Hedge Fund Alpha

Log In

Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Don’t have an account?

Subscribe now and get 7 days free!

HFA Padded

The post above is drafted by the collaboration of the Hedge Fund Alpha Team.